Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nicotine patches + bupropion
- Development stage
- Unknown
- Lead developer
- Duke University
- Modality
- Small Molecules
- Administration
- Transdermal, Oral
01
Overview
Nicotine patches + bupropion is a combination pharmacological treatment for nicotine dependence, specifically evaluated in the ConNic3 trial by Duke University. The regimen utilizes transdermal nicotine patches to provide a controlled dose of nicotine, reducing withdrawal symptoms by acting as an agonist at nicotinic acetylcholine receptors (nAChRs). Bupropion, an antidepressant, serves as a norepinephrine-dopamine reuptake inhibitor (NDRI) and a non-competitive antagonist at nAChRs, which helps to diminish the urge to smoke and the reinforcing pleasure derived from nicotine. This combination is often employed in a stepped-care approach, where bupropion is added as a rescue therapy for individuals who do not achieve early success with nicotine replacement therapy alone.
- Brand names
- ZybanNicoderm CQ
- Other names
- nicotine replacement therapy + bupropionNRT + bupropion
02
Targets
NET (Norepinephrine Transporter)Nicotinic Acetylcholine ReceptorSIGMAR1 (Sigma non-opioid intracellular receptor 1)DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on nicotine patches + bupropion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nicotine patches + bupropion.